In short
- Ten drugs have Medicare negotiated prices in 2026, from Januvia at $113 to Imbruvica at $9,319 for a 30-day supply.
- Fifteen more drugs, including Ozempic, Rybelsus and Wegovy at $274, get negotiated prices on January 1, 2027. CMS estimates enrollees will save about $685 million out of pocket that year.
- The third round, announced January 27, 2026, includes the first Part B drugs given in a doctor's office, with prices starting in 2028.
- A negotiated price is what your plan pays, not your copay. Your cost still depends on your plan's deductible, tiers and coinsurance.
Medicare has now been paying negotiated prices for its first 10 drugs for more than eight months, a second round takes effect in January, and a third is underway. With 2027 drug plans about to post and open enrollment starting October 15, here is where things stand and what it means for your medications.
What is Medicare drug price negotiation?
Under the Inflation Reduction Act of 2022, Medicare can negotiate prices directly with drugmakers for certain high-cost brand-name drugs. The negotiated price is what Medicare drug coverage pays for a 30-day supply. It is not your copay.
The program runs in rounds. Each round picks a set of drugs, and the agreed prices take effect on January 1 of a later year.
Which drugs got negotiated prices in 2026?
The first 10 prices took effect January 1, 2026. These are for a 30-day supply.
| Drug | Commonly used for | 2026 negotiated price |
|---|---|---|
| Januvia | Type 2 diabetes | $113 |
| Fiasp and NovoLog | Insulin | $119 |
| Farxiga | Diabetes, heart failure, kidney disease | $178.50 |
| Jardiance | Diabetes, heart failure | $197 |
| Xarelto | Blood thinner | $197 |
| Eliquis | Blood thinner | $231 |
| Entresto | Heart failure | $295 |
| Enbrel | Rheumatoid arthritis and other conditions | $2,355 |
| Stelara | Psoriasis, Crohn's disease | $4,695 |
| Imbruvica | Blood cancers | $9,319 |
Does a negotiated price lower what you pay?
Sometimes, and it depends on your plan. If you are still in your deductible, or your plan charges coinsurance (a percentage of the drug's cost), a lower price usually lowers your share. If your plan charges a flat copay for that drug, you may see no change at the counter.
Other rules may matter more. Insulin is already capped at $35 a month. And your yearly out-of-pocket spending on covered Part D drugs stops at $2,100 in 2026. If you were already hitting that cap, a lower price on one drug may not change your yearly total. Our guide to the Part D out-of-pocket cap explains what counts.
What changes on January 1, 2027?
Fifteen more drugs get negotiated prices. CMS estimates people with Medicare will save about $685 million out of pocket in 2027.
| Drug | 2027 negotiated price (30 days) |
|---|---|
| Ozempic, Rybelsus, Wegovy | $274 |
| Trelegy Ellipta | $175 |
| Breo Ellipta | $67 |
| Linzess | $136 |
| Tradjenta | $78 |
| Janumet, Janumet XR | $80 |
| Vraylar | $770 |
| Xifaxan | $1,000 |
| Otezla, Otezla XR | $1,650 |
| Austedo, Austedo XR | $4,093 |
| Ofev | $6,350 |
| Xtandi | $7,004 |
| Ibrance | $7,871 |
| Calquence | $8,600 |
| Pomalyst | $8,650 |
The 2027 Part D rules are also set. The maximum deductible rises from $615 to $700, and the out-of-pocket cap rises from $2,100 to $2,400. A drug's negotiated price does not tell you its tier or copay on a 2027 plan. That comes from each plan's formulary, the list of drugs it covers.
What about Wegovy and the GLP-1 Bridge?
The Medicare GLP-1 Bridge, which started July 1, 2026, is separate from negotiation. It lets people who qualify get Wegovy, Zepbound KwikPen or Foundayo for weight management for $50 a month, regardless of income. In April, CMS extended it through December 31, 2027.
To qualify, you must be 18 or older, have Part D coverage, have a body mass index in set ranges (35 or higher, or lower with certain heart, blood vessel, blood pressure, kidney or prediabetes conditions), and get a prior approval form from your prescriber. People with type 2 diabetes, moderate to severe sleep apnea or fatty liver disease are not eligible for the Bridge. The $50 does not count toward your deductible or yearly cap. Talk to your doctor about whether any of these drugs is right for you.
What comes after 2027?
On January 27, 2026, CMS named 15 drugs for the third round, with prices starting in 2028. For the first time, the list includes Part B drugs, the kind given in a doctor's office or clinic. The list includes Trulicity, Biktarvy, Orencia, Cosentyx, Erleada, Kisqali, Entyvio, Verzenio, Botox, Lenvima, Xolair, Rexulti, Xeljanz, Anoro Ellipta and Cimzia. Tradjenta was picked for renegotiation.
Part B drugs matter for people on Original Medicare, who generally pay 20% coinsurance on them unless a Medicare Supplement plan covers it.
What should you do this fall?
- Write down every medication, with the dose and how often you take it.
- Check whether any of them are on the 2026 or 2027 lists above.
- Read your plan's Annual Notice of Change when it arrives this month.
- Compare 2027 Part D plans on total yearly cost once they post, not just premium.
- If money is tight, check whether you qualify for Extra Help.
For the rest of this year's numbers, see 2026 Medicare costs at a glance. For unbiased help, call 1-800-MEDICARE (1-800-633-4227), 24 hours a day, 7 days a week (TTY 1-877-486-2048), or Nebraska SHIP (formerly SHIIP) at 1-800-234-7119.
Frequently asked questions
Ten Part D drugs: Eliquis, Jardiance, Xarelto, Januvia, Farxiga, Entresto, Enbrel, Imbruvica, Stelara, and the insulins Fiasp and NovoLog. Their negotiated prices took effect January 1, 2026. The prices range from $113 for a 30-day supply of Januvia to $9,319 for Imbruvica. These are prices for Medicare drug coverage, not the copay you see at the pharmacy, which depends on your plan.
Yes. Ozempic, Rybelsus and Wegovy share a negotiated price of $274 for a 30-day supply starting January 1, 2027. They are part of the second group of 15 drugs. Your own cost will still depend on how your 2027 plan covers the drug, including its deductible and tier. Separately, the Medicare GLP-1 Bridge offers Wegovy for weight loss at $50 a month to people who qualify, through December 31, 2027.
It can, but not always. If you are paying the full price during your deductible, or your plan charges a percentage of the drug's cost, a lower price usually means you pay less. If your plan charges a flat copay for the drug, your copay may not change. Your total drug spending is also capped each year, at $2,100 in 2026 and $2,400 in 2027.
Yes, for drug coverage. The negotiated prices apply to covered Part D drugs, whether you get Part D through a standalone drug plan or through a Medicare Advantage plan that includes drug coverage. They do not apply if you have no Part D coverage. Starting in 2028, the third round also sets prices for some Part B drugs that are given in a doctor's office or clinic.
In 2028. On January 27, 2026, CMS picked 15 drugs for the third round, and for the first time the list includes Part B drugs, which are usually given by a doctor or clinic. The 15 drugs include Trulicity, Biktarvy, Orencia, Entyvio and Botox, among others. The diabetes drug Tradjenta was also selected for renegotiation. Prices from this round take effect in 2028.
Sources
- CMS: Negotiated prices for initial price applicability year 2026 (fact sheet) (opens in a new tab)
- CMS: Negotiated prices for initial price applicability year 2027 (fact sheet) (opens in a new tab)
- CMS: Selected drug list for initial price applicability year 2028 (fact sheet) (opens in a new tab)
- Medicare.gov: Medicare GLP-1 Bridge (CMS Product No. 12234) (opens in a new tab)
- CMS: Status update on the GLP-1 Bridge and BALANCE Model for CY 2027 (April 21, 2026) (opens in a new tab)
- CMS: CY 2027 Medicare Advantage and Part D Rate Announcement (opens in a new tab)
We do not offer every plan available in your area. Any information we provide is limited to those plans we do offer in your area. Please contact Medicare.gov or 1-800-MEDICARE to get information on all of your options. 1-800-MEDICARE (1-800-633-4227) is available 24 hours a day, 7 days a week. TTY users can call 1-877-486-2048.
